Daniel van Wamelen (The Maurice Wohl Clinical Neuroscience Institute, King’s College London, UK) discusses non-motor symptoms in Parkinson’s disease (PD) and the repurposing of existing medication in PD to target new areas such as cognition.
Questions
- Are objective measures available for non-motor symptoms of Parkinson’s disease (PD), similar to objective measures for motor symptoms? (0:04)
- How can existing drugs for PD be repurposed to target non-motor symptoms in PD? (2:06)
- What is the effect of advanced therapies, such as apomorphine and intrajejunal levodopa infusion, on non-motor symptoms in PD? (4:29)
View Part 1 of this expert interview here.
Speaker disclosure: Daniel van Wamelen has nothing to disclose in relation to this video interview.
Filmed at the American Academy of Neurology (AAN) Annual Meeting, Philadelphia, USA, May 2019.